Guardant Health Inc

Guardant Health Inc Stock Forecast & Price Prediction

Live Guardant Health Inc Stock (GH) Price
$23.00

4

Ratings

  • Buy 4
  • Hold 0
  • Sell 0
Disclaimer : Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance. This information is for educational purposes only and should not be construed as advice to buy or sell any security.

Stock Price

$23.00

P/E Ratio

-5.37

Volume Traded Today

$2.0M

Dividend

Dividends not available for GH

52 Week High/low

37.04/15.81

Guardant Health Inc Market Cap

$2.69B

๐Ÿ›‘ Alert: These ten stocks could have higher potential than $GH ๐Ÿ›‘

Before you buy GH you'll want to see this list of ten stocks that have huge potential. Want to see if GH made the cut? Enter your email below

GH Summary

From what 4 stock analysts predict, the share price for Guardant Health Inc (GH) might increase by 75.04% in the next year. This is based on a 12-month average estimation for GH. Price targets go from $19 to $50. The majority of stock analysts believe GH is a buy. Please note analyst price targets are not guaranteed and could be missed completely.

GH Analyst Ratings

Guardant Health Inc has a total of 4 Wall St Analyst ratings. There are 4 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Guardant Health Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.

GH stock forecast by analyst

These are the latest 20 analyst ratings of GH.

Analyst/Firm

Rating

Price Target

Change

Date

Eve Burstein
Bernstein

Outperform

$35

Maintains

Oct 30, 2024

Leerink Partners

Outperform

$50

Maintains

Oct 17, 2024
Dan Leonard
UBS

Buy

$40

Maintains

Aug 21, 2024
David Westenberg
Piper Sandler

Overweight

$34

Maintains

Aug 13, 2024
Julia Qin
JP Morgan

Overweight

$48

Maintains

Aug 8, 2024
Alex Nowark
Craig-Hallum

Buy

$37

Maintains

Aug 8, 2024
Patrick Donnelly
Citigroup

Buy

$45

Maintains

Aug 8, 2024
Dan Brennan
TD Cowen

Buy

$42

Maintains

Aug 8, 2024
Mark Massaro
BTIG

Buy

$50

Maintains

Jul 30, 2024
Michael Ryskin
B of A Securities

Buy

$40

Maintains

Jul 18, 2024
Matthew Sykes
Goldman Sachs

Buy

$32

Maintains

Jul 17, 2024
Subbu Nambi
Guggenheim

Buy

$36

Upgrade

Jun 28, 2024
Kyle Mikson
Canaccord Genuity

Buy

$38

Maintains

Jun 4, 2024
Tycho Peterson
Jefferies

Buy

$32

Initiates

Jun 3, 2024
Mason Carrico
Stephens & Co.

Overweight

$44

Reiterates

May 24, 2024
Kyle Mikson
Canaccord Genuity

Buy

$30

Maintains

Apr 29, 2024
Alex Nowark
Craig-Hallum

Buy

$28

Assumes

Apr 24, 2024
Matthew Sykes
Goldman Sachs

Buy

$28

Maintains

Apr 15, 2024
Subbu Nambi
Guggenheim

Neutral


Reiterates

Apr 5, 2024
David Westenberg
Piper Sandler

Overweight

$30

Maintains

Feb 26, 2024

GH Company Information

What They Do: Precision oncology company offering blood and tissue tests.

Business Model: The company generates revenue through its comprehensive suite of cancer diagnostic tests, including liquid biopsy and tissue testing services. It also provides integrated software solutions and development services for clinical and biopharmaceutical customers, creating a diverse revenue stream from both product sales and partnerships.

Other Information: Guardant Health has a collaboration with Illumina, Inc. to enhance cancer research through shared specimen samples. Founded in 2011 and based in Palo Alto, California, the company leverages advanced technology, including AI, to improve cancer detection and treatment options.
GH
Guardant Health Inc (GH)

When did it IPO

2018

Staff Count

1,768

Country

United States

Sector/Industry

Healthcare/Diagnostics & Research

CEO

Dr. Helmy Eltoukhy Ph.D.

Market Cap

$2.69B

Guardant Health Inc (GH) Financial Data

In 2023, GH generated $563.9M in revenue, which was a increase of 25.45% from the previous year. This can be seen as a signal that GH's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.

Revenue From 2020

$286.7M

Revenue From 2021

$373.7M

30.32 %
From Previous Year

Revenue From 2022

$449.5M

20.31 %
From Previous Year

Revenue From 2023

$563.9M

25.45 %
From Previous Year
  • Revenue TTM $643.8M
  • Operating Margin TTM -56.6%
  • Gross profit TTM $336.9M
  • Return on assets TTM -15.4%
  • Return on equity TTM -337.2%
  • Profit Margin -76.2%
  • Book Value Per Share -0.01%
  • Market capitalisation $2.69B
  • Revenue for 2021 $373.7M
  • Revenue for 2022 $449.5M
  • Revenue for 2023 $563.9M
  • EPS this year (TTM) $-4.11

Guardant Health Inc (GH) Latest News

News Image

Wed, 30 Oct 2024

Sentiment - NEUTRAL

Source - The Motley Fool

Summary - Free publicity can significantly boost sales for new products, indicating a potential positive impact on revenue and market visibility for companies launching such items.

Why It Matters - Free publicity can significantly boost sales, impacting revenue projections and market perception, which may lead to stock price increases for companies involved.

News Image

Wed, 30 Oct 2024

Sentiment - NEGATIVE

Source - Zacks Investment Research

Summary - Guardant Health (GH) is not expected to meet key criteria for a positive earnings report in its upcoming release. Investors should be prepared for this potential outcome.

Why It Matters - Guardant Health's potential earnings miss could lead to a drop in stock price, signaling weak performance and impacting investor sentiment and confidence in the company's future.

News Image

Wed, 30 Oct 2024

Sentiment - NEUTRAL

Source - Business Wire

Summary - Guardant Health's blood-based colorectal cancer screening product, Shield, has been named in TIME's annual list of the Best Inventions, recognizing its impact in precision oncology.

Why It Matters - Guardant Health's inclusion in TIME's Best Inventions highlights its innovation and credibility in oncology, potentially boosting investor confidence and interest in the companyโ€™s future growth.

News Image

Mon, 28 Oct 2024

Sentiment - NEUTRAL

Source - Business Wire

Summary - Guardant Health will present data on blood-based testing's impact on colorectal cancer screening adherence at the ACG 2024 Annual Meeting in Philadelphia, Oct. 25-30, 2024.

Why It Matters - Guardant Health's presentation on blood-based cancer testing could enhance its market position and drive demand for its products, potentially boosting stock performance and investor interest.

News Image

Thu, 24 Oct 2024

Sentiment - NEUTRAL

Source - Business Wire

Summary - Guardant Health appointed Roberto A. Mignone, Founder of Bridger Management LLC, to its board of directors, effective immediately, enhancing its healthcare expertise.

Why It Matters - Roberto Mignone's appointment to Guardant Health's board enhances strategic insights and governance, potentially boosting investor confidence and impacting stock performance.

News Image

Tue, 15 Oct 2024

Sentiment - NEUTRAL

Source - Business Wire

Summary - Guardant Health, Inc. (Nasdaq: GH) will report Q3 2024 financial results on November 6, 2024, after market close, with a conference call at 1:30 PM PT. Webcast available on their website.

Why It Matters - Guardant Health's upcoming financial results announcement could impact stock performance, providing insights into growth, profitability, and market position in precision oncology.

...

GH Frequently asked questions

The highest forecasted price for GH is $50 from David Westenberg at Piper Sandler.

The lowest forecasted price for GH is $19 from from

The GH analyst ratings consensus are 4 buy ratings, 0 hold ratings, and 0 sell ratings.